Can Ozempic Cause Gastroparesis? What the Science Says

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Targeted Safety Concerns

If you or someone you know has developed severe stomach paralysis after taking Ozempic, you may be wondering whether the drug is to blame. The medical community has long recognized that some medications can affect digestive function, and recent reports have raised questions about a possible link between GLP-1 agonists like Ozempic and gastroparesis. This page reviews the current evidence, what it can and cannot show, and what that means for patients.

Understanding Ozempic and Gastroparesis: A Medical Overview

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes and, in some formulations, for weight loss. Its mechanism of action includes slowing gastric emptying, which can contribute to gastrointestinal symptoms. Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, and abdominal pain. Clinical presentation and diagnosis of gastroparesis typically involve a history of these symptoms and confirmatory gastric emptying studies. Evidence from clinical trials indicates that gastrointestinal adverse reactions are significantly more common in patients taking Ozempic compared to placebo. In pooled placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% of those on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and diarrhea occurred during dose escalation. Discontinuation due to gastrointestinal adverse reactions was higher in Ozempic-treated patients: 3.1% for 0.5 mg and 3.8% for 1 mg, compared to 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred in 30.8% of patients on 1 mg and 34.0% on 2 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions reported at frequencies below 5% include dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms overlap with those of gastroparesis, suggesting a potential mechanistic link through delayed gastric emptying.

Post-Marketing Surveillance and Evidence of Harm

Post-marketing surveillance data from the FDA Adverse Event Reporting System (FAERS) further highlight the association. Among adverse events most frequently reported with Ozempic, impaired gastric emptying appears with 2,693 reports (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). Other commonly reported gastrointestinal events include nausea (8,652 reports), vomiting (5,578 reports), diarrhea (5,274 reports), constipation (3,859 reports), dyspepsia (1,374 reports), and abdominal distension (1,408 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). These data indicate that a substantial number of patients have experienced symptoms consistent with gastroparesis while using Ozempic. The mechanistic pathways linking Ozempic to gastroparesis involve its action as a GLP-1 receptor agonist, which slows gastric emptying. This pharmacological effect is intended to improve glycemic control but can become pathological in some individuals, leading to clinically significant delayed gastric emptying and gastroparesis. The timeline between exposure and documented harm can vary; symptoms often emerge during dose escalation, as noted in clinical trials, but may also develop after prolonged use. The FAERS data do not provide precise timing, but the high number of reports suggests that harm can occur within weeks to months of starting treatment.

Legal Considerations for Affected Patients

Regarding the adequacy of warnings, the Ozempic prescribing information includes gastrointestinal adverse reactions in the label, but it does not explicitly list gastroparesis as a specific adverse reaction. The label mentions impaired gastric emptying in the context of FAERS reports but does not provide a dedicated warning for gastroparesis. This may be considered insufficient for patients and healthcare providers to fully assess the risk. For affected patients, attorney-related considerations include the potential for product liability claims if it can be demonstrated that the manufacturer failed to adequately warn about the risk of gastroparesis. Patients who have developed gastroparesis after using Ozempic may seek legal counsel to explore compensation for medical expenses, pain and suffering, and lost wages. The timeline between exposure and harm is critical for establishing causation, and medical records documenting the onset of symptoms relative to Ozempic use are essential. In summary, the evidence from clinical trials and post-marketing surveillance supports a link between Ozempic and gastroparesis, mediated by delayed gastric emptying. The frequency of gastrointestinal adverse reactions is dose-dependent, and the FAERS data show thousands of reports of impaired gastric emptying. The adequacy of warnings in the product label may be questioned, and patients affected by gastroparesis may have legal options. A thorough evaluation by a medical professional and consultation with an attorney experienced in pharmaceutical litigation are recommended for those who believe they have been harmed.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) slows gastric emptying as part of its mechanism of action. In some individuals, this can lead to clinically significant delayed gastric emptying and gastroparesis, a condition characterized by nausea, vomiting, early satiety, and abdominal pain. Clinical trials and post-marketing data show higher rates of gastrointestinal adverse reactions in Ozempic users, including impaired gastric emptying (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What legal options do I have if I developed gastroparesis after taking Ozempic?

If you developed gastroparesis after using Ozempic, you may have grounds for a product liability claim, particularly if the manufacturer failed to adequately warn about the risk. Consulting with an attorney experienced in pharmaceutical litigation can help you explore compensation for medical expenses, pain and suffering, and lost wages. Medical records documenting the onset of symptoms relative to Ozempic use are essential for establishing causation.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.